Effective treatment of cerebral mucormycosis associated with brain surgery

Related Experiment Video

Updated: Apr 20, 2026

Heterotopic Mucosal Engrafting Procedure for Direct Drug Delivery to the Brain in Mice

Heterotopic Mucosal Engrafting Procedure for Direct Drug Delivery to the Brain in Mice

Published on: July 16, 2014

Omar Chamdine¹, Aditya H Gaur, Alberto Broniscer

¹From the *Department of Oncology and †Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN; and ‡Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN.

The Pediatric Infectious Disease Journal

|November 25, 2014

Abstract:

Isolated cerebral mucormycosis is rare. We describe a patient with a brain tumor and a surgically-related Rhizopus oryzae brain abscess. Her abscess was effectively treated with posaconazole, micafungin and colony-stimulating factor followed by posaconazole alone. To our knowledge, cerebral mucormycosis secondary to brain surgery had not been previously reported.

More Related Videos

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Published on: June 2, 2023

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

Related Concept Videos

Brain Abscess l: Introduction

Brain Abscess l: Introduction

A brain abscess is a focal, intracerebral infection characterized by a localized collection of pus within the brain parenchyma, resulting from microbial invasion and the body’s inflammatory response. It progresses through stages: early and late cerebritis, followed by early and late capsule formation, reflecting tissue destruction, immune response, and eventual encapsulation.Etiology and PathogenesisCausative organisms vary with source and host factors, often involving polymicrobial...

Articles linked to this work by shared authors, journal, and citation graph.

Safety, antiviral activity, and pharmacokinetics of long-acting cabotegravir plus long-acting rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): week 96 and end-of-study results from a multinational, phase 1/2, single-arm trial.

The Lancet. Child & adolescent health·2026

Quality indicators for the care of children with CNS tumors: An international modified Delphi study.

Neuro-oncology advances·2026

Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.

Leukemia & lymphoma·2026

PTPN11-Related Noonan Syndrome Predisposes to Multifocal Low-Grade CNS Tumors Harboring FGFR1 Variants.

Research square·2026

Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial.

The lancet. HIV·2026

Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study.

The lancet. HIV·2026

See all related articles